受强制性开放获取政策约束的文章 - Zheng Zhao了解详情
无法在其他位置公开访问的文章：6 篇
Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl)-2-(dimethylamino) ethanone (CHMFL-FLT3-122) as a Potent and Orally …
X Li, A Wang, K Yu, Z Qi, C Chen, W Wang, C Hu, H Wu, J Wu, Z Zhao, ...
Journal of Medicinal Chemistry 58 (24), 9625–9638, 2015
强制性开放获取政策： 中国科学院, 国家自然科学基金委员会
Design, synthesis, and antifungal activities of 3-acyl thiotetronic acid derivatives: new fatty acid synthase inhibitors
P Lv, Y Chen, Z Zhao, T Shi, X Wu, J Xue, QX Li, R Hua
Journal of agricultural and food chemistry 66 (4), 1023-1032, 2018
强制性开放获取政策： 国家自然科学基金委员会
Discovery of a highly selective STK16 kinase inhibitor
F Liu, J Wang, X Yang, B Li, H Wu, S Qi, C Chen, X Liu, K Yu, W Wang, ...
ACS chemical biology 11 (6), 1537-1543, 2016
强制性开放获取政策： 中国科学院, 国家自然科学基金委员会
Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL …
X Liang, F Lv, B Wang, K Yu, H Wu, Z Qi, Z Jiang, C Chen, A Wang, ...
Journal of Medicinal Chemistry 60 (5), 1793-1816, 2017
强制性开放获取政策： 中国科学院, 国家自然科学基金委员会
Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available …
Q Wang, F Liu, B Wang, F Zou, C Chen, X Liu, A Wang, S Qi, W Wang, ...
Journal of Medicinal Chemistry 59 (8), 3964-3979, 2016
强制性开放获取政策： 中国科学院, 国家自然科学基金委员会
Deriving chemically essential interactions based on active site alignments and quantum chemical calculations: A case study on glycoside hydrolases
Y Zhang, Z Zhao, H Liu
ACS Catalysis 5 (4), 2559-2572, 2015
强制性开放获取政策： 国家自然科学基金委员会
可在其他位置公开访问的文章：27 篇
Developing irreversible inhibitors of the protein kinase cysteinome
Q Liu, Y Sabnis, Z Zhao, T Zhang, SJ Buhrlage, LH Jones, NS Gray
Chemistry & biology 20 (2), 146-159, 2013
强制性开放获取政策： US National Institutes of Health
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
Z Zhao, H Wu, L Wang, Y Liu, S Knapp, Q Liu, NS Gray
ACS chemical biology 9 (6), 1230-1241, 2014
强制性开放获取政策： Canadian Institutes of Health Research, Genome Canada, Wellcome Trust
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor
HG Kim, L Tan, EL Weisberg, F Liu, P Canning, HG Choi, SA Ezell, H Wu, ...
ACS chemical biology 8 (10), 2145-2150, 2013
强制性开放获取政策： US National Institutes of Health, Canadian Institutes of Health Research …
Brain penetrant LRRK2 inhibitor
HG Choi, J Zhang, X Deng, JM Hatcher, MP Patricelli, Z Zhao, DR Alessi, ...
ACS medicinal chemistry letters 3 (8), 658-662, 2012
强制性开放获取政策： US National Institutes of Health
Determining cysteines available for covalent inhibition across the human kinome
Z Zhao, Q Liu, S Bliven, L Xie, PE Bourne
Journal of Medicinal Chemistry 60 (7), 2879–2889, 2017
强制性开放获取政策： US National Institutes of Health
Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics
Q Liu, S Kirubakaran, W Hur, M Niepel, K Westover, CC Thoreen, J Wang, ...
Journal of Biological Chemistry 287 (13), 9742-9752, 2012
强制性开放获取政策： US National Institutes of Health, Howard Hughes Medical Institute
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and …
E Weisberg, Q Liu, E Nelson, AL Kung, AL Christie, R Bronson, M Sattler, ...
Leukemia 26 (10), 2233-2244, 2012
强制性开放获取政策： US National Institutes of Health
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma
H Wu, W Wang, F Liu, EL Weisberg, B Tian, Y Chen, B Li, A Wang, ...
ACS chemical biology 9 (5), 1086-1091, 2014
强制性开放获取政策： US National Institutes of Health, 中国科学院
Crystal Structure of the GRAS Domain of SCARECROW-LIKE7 in Oryza sativa
S Li, Y Zhao, Z Zhao, X Wu, L Sun, Q Liu, Y Wu
The Plant Cell 28 (5), 1025-1034, 2016
强制性开放获取政策： 国家自然科学基金委员会
Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome
Z Zhao, L Xie, PE Bourne
PLoS One 12 (6), e0179936, 2017
强制性开放获取政策： US National Institutes of Health, German Research Foundation
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia
H Wu, C Hu, A Wang, EL Weisberg, Y Chen, CH Yun, W Wang, Y Liu, ...
Leukemia 30 (1), 173-181, 2016
强制性开放获取政策： US National Institutes of Health, 中国科学院, 国家自然科学基金委员会
Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology
Z Zhao, C Martin, R Fan, PE Bourne, L Xie
BMC bioinformatics 17, 1-12, 2016
强制性开放获取政策： US National Science Foundation, US National Institutes of Health
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
A Wang, XE Yan, H Wu, W Wang, C Hu, C Chen, Z Zhao, P Zhao, X Li, ...
Oncotarget 7 (43), 69760, 2016
强制性开放获取政策： US National Institutes of Health, 中国科学院, 国家自然科学基金委员会
Delineation of polypharmacology across the human structural kinome using a functional site interaction fingerprint approach
Z Zhao, L Xie, L Xie, PE Bourne
Journal of medicinal chemistry 59 (9), 4326-4341, 2016
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定